Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2025 15:40 ET | Source: Tevogen Bio Inc

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services...
September 17, 2025 09:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical response and promising signals regarding the...
September 17, 2025 07:00 ET | Source: AccuStem Sciences, Inc.

AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning

PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk...
September 16, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK,...
September 11, 2025 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available...
September 10, 2025 09:00 ET | Source: Eleos Health

Eleos Launches Smarter Support for Group Therapy and SUD Care

New Groups capability represents the first AI solution to deliver individual speaker summaries for group therapy sessions, enabling SUD organizations to achieve documentation compliance at scale ...
September 08, 2025 20:58 ET | Source: Valley Wellness

Valley Wellness to open luxury behavioral health facility in Corona, CA

CORONA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Valley Wellness, a California-based behavioral health treatment company, has announced the opening of its first facility in Corona, CA. The company...
September 08, 2025 08:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,...
September 08, 2025 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by...
September 05, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data...